(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Cogent Biosciences's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast COGT's revenue for 2026 to be $3,965,620,293, with the lowest COGT revenue forecast at $2,277,129, and the highest COGT revenue forecast at $12,956,864,465. On average, 5 Wall Street analysts forecast COGT's revenue for 2027 to be $25,255,866,339, with the lowest COGT revenue forecast at $6,181,266,888, and the highest COGT revenue forecast at $69,497,979,522.
In 2028, COGT is forecast to generate $37,545,645,840 in revenue, with the lowest revenue forecast at $22,532,192,247 and the highest revenue forecast at $66,697,110,753.